{
  "ticker": "FRE",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02961061",
  "id": "02961061",
  "pages": 20,
  "price_sensitive": false,
  "date": "20250623",
  "time": "1506",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250623/pdf/06l0kp5csl810l.pdf",
  "summary": "**Summary of Firebrick Pharma Investor Presentation (23 June 2025):**  \n\n- **Strategic Shift**: Marketing Nasodine as a **nasal antiseptic** (not just a cold treatment) to bypass regulatory hurdles and enable immediate sales in multiple markets (e.g., US, Singapore, Fiji).  \n- **Commercial Progress**:  \n  - **US**: Online sales launched April 2024 as cosmetic nasal cleanser; FY26 goals include pharmacy distribution and scaling to 5,000 customers.  \n  - **SE Asia**: Philippines PFDA filing expected Sep 2025; partner SV More Pharma to handle marketing (FRE earns A$2.60/unit).  \n  - **Retail**: Guardian pharmacy distribution secured in Australia (Jan 2025); won \"best newcomer\" in Cough & Cold category.  \n- **Clinical Validation**: Peer-reviewed study (June 2025) confirms Nasodine\u2019s **40% symptom reduction benefit** when used early (first 24 hours of cold onset).  \n- **Market Potential**: Targets 17 billion global URTI cases/year; potential applications in pandemic preparedness (stops viral shedding) and MRSA prevention.  \n- **Financials**: Current market cap **A$15\u201320m**; low cash burn but requires further funding for growth.  \n\n**Material Omissions**: No capital raising details, financials (e.g., cash balance), or specific timelines (e.g., Philippines approval). Focus is on commercial strategy and clinical validation.",
  "usage": {
    "prompt_tokens": 4615,
    "completion_tokens": 310,
    "total_tokens": 4925,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-23T05:36:33.014525"
}